Skip to Content

Ariad Pharmaceuticals Inc.

Company NameAriad Pharmaceuticals Inc.
Stock SymbolARIA

The Firm announces an investigation on behalf of Ariad Pharmaceuticals Inc. (“Ariad” or the “Company”) (NASDAQ: ARIA) investors concerning the Company and its officers’ possible violations of federal securities laws.

Ariad is an oncology company that engages in the discovery, development and commercialization of drugs for cancer patients in the United States and internationally.

On October 6, 2016, a report entitled, "How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price," highlighted the ways in which Ariad was able to inflate the price for its leukemia drug, Iclusig. Following the FDA’s decision to put Iclusig back on the market, but with a reduced recommended dose and more restricted approved use, Ariad allegedly ultimately "embarked on a series of massive price increases" for its now-niche drug, rather than reduce its price to accurately reflect the FDA’s recommendations. Then, on October 14, 2016, Senator Bernie Sanders criticized the Company for hiking the prices of its drugs.

Following this news, Ariad shares fell nearly 15%, or $1.93 per share, to close at $11.14 on October 14, 2016.

If you purchased Ariad securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Submit Your Information

If you suffered a loss on your Ariad Pharmaceuticals Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd